Anti-angiogenic therapy increases intratumoral adenovirus distribution by inducing collagen degradation

Gene Therapy

Volumn 20, Issue 3, 2013, Pages 318-327

  Thaci, B ^a   Ulasov, I V ^a   Ahmed, A U ^a   Ferguson, S D ^a   Han, Y ^a   Lesniak, M S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; COLLAGEN TYPE 4; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; ONCOLYTIC ADENOVIRUS; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC GENE THERAPY; ARTICLE; COLLAGEN DEGRADATION; CONTROLLED STUDY; DRUG DISTRIBUTION; EXTRACELLULAR MATRIX; GENE EXPRESSION; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; UPREGULATION; VIRUS REPLICATION;

ADENOVIRIDAE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, BLOCKING; CELL LINE, TUMOR; COLLAGEN; COMBINED MODALITY THERAPY; GENETIC THERAPY; GENETIC VECTORS; GLIOMA; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INJECTIONS, INTRALESIONAL; KAPLAN-MEIER ESTIMATE; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; POLYLYSINE; PROMOTER REGIONS, GENETIC; PROTEOLYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE;

EID: 84874768191     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2012.42     Document Type: Article

References (37)

1. Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il'yasova D et al. Brain tumor epidemiology: consensus from the brain tumor epidemiology consortium. Cancer 2008; 113(7 Suppl): 1953-1968.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
3. Ulasov IV, Zhu ZB, Tyler MA, Han Y, Rivera AA, Khramtsov A et al. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther 2007; 18: 589-602.
4. Wojton J, Kaur B. Impact of tumor microenvironment on oncolytic viral therapy. Cytokine Growth Factor Rev 2010; 21: 127-134.
5. Pluen A, Boucher Y, Ramanujan S, McKee TD, Gohongi T, di Tomaso E et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci USA 2001; 98: 4628-4633.
6. McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res 2006; 66: 2509-2513.
7. Kim JH, Lee YS, Kim H, Huang JH, Yoon AR, Yun CO. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst 2006; 98: 1482-1493.
8. Ganesh S, Gonzalez Edick M, Idamakanti N, Abramova M, Vanroey M, Robinson M et al. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res 2007; 67: 4399-4407.
9. Hong CS, Fellows W, Niranjan A, Alber S, Watkins S, Cohen JB et al. Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection. Gene Therapy 2010; 17: 1200-1205.
10. Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 2009; 15: 4589-4599.
11. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733-4740.
12. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I et al. Phase II trial of singleagent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27: 740-745.
13. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999; 284: 808-812.
14. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6: 553-563.
15. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007; 13: 3942-3950.
16. Hu B, Guo P, Bar-Joseph I, Imanishi Y, Jarzynka MJ, Bogler O et al. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene 2007; 26: 5577-5586.
17. Yun YJ, Li SH, Cho YS, Park JW, Chun YS. Survivin mediates prostate cell protection by HIF-1alpha against zinc toxicity. Prostate 2010; 70: 1179-1188.
18. Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 2009; 8: 1867-1877.
19. Libertini S, Iacuzzo I, Perruolo G, Scala S, Ierano C, Franco R et al. Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947. Clin Cancer Res 2008; 14: 6505-6514.
20. Reichert S, Rodel C, Mirsch J, Harter PN, Tomicic MT, Mittelbronn M et al. Survivin inhibition and DNA double-strand break repair: A molecular mechanism to overcome radioresistance in glioblastoma. Radiother Oncol 2011; 101: 51-58.
21. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010; 12: 233-242.
22. Mok W, Boucher Y, Jain RK. Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. Cancer Res 2007; 67: 10664-10668.
23. Chernov AV, Sounni NE, Remacle AG, Strongin AY. Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells. J Biol Chem 2009; 284: 12727-12734.
24. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732.
25. Elstner A, Holtkamp N, von Deimling A. Involvement of Hif-1 in desferrioxamineinduced invasion of glioblastoma cells. Clin Exp Metastasis 2007; 24: 57-66.
26. Lu KV, Jong KA, Rajasekaran AK, Cloughesy TF, Mischel PS. Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Lab Invest 2004; 84: 8-20.
27. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
28. Hamerlik P, Lathia JD, Rasmussen R, Wu Q, Bartkova J, Lee M et al. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med 2012; 209: 507-520.
29. Lee J, Yu H, Choi K, Choi C. Differential dependency of human cancer cells on vascular endothelial growth factor-mediated autocrine growth and survival. Cancer Lett 2011; 309: 145-150.
30. Kargiotis O, Chetty C, Gondi CS, Tsung AJ, Dinh DH, Gujrati M et al. Adenovirusmediated transfer of siRNA against MMP-2 mRNA results in impaired invasion and tumor-induced angiogenesis, induces apoptosis in vitro and inhibits tumor growth in vivo in glioblastoma. Oncogene 2008; 27: 4830-4840.
31. Lamfers ML, Gianni D, Tung CH, Idema S, Schagen FH, Carette JE et al. Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma. Cancer Res 2005; 65: 9398-9405.
32. Zhang W, Fulci G, Buhrman JS, Stemmer-Rachamimov AO, Chen JW, Wojtkiewicz GR et al. Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma. Mol Ther 2011; 20: 37-45.
33. Guse K, Ranki T, Ala-Opas M, Bono P, Sarkioja M, Rajecki M et al. Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses. Mol Cancer Ther 2007; 6: 2728-2736.
34. Gutermann A, Mayer E, von Dehn-Rothfelser K, Breidenstein C, Weber M, Muench M et al. Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells. Hum Gene Ther 2006; 17: 1241-1253.
35. Guse K, Sloniecka M, Diaconu I, Ottolino-Perry K, Tang N, Ng C et al. Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. J Virol 2010; 84: 856-866.
36. Fuh G, Wu P, Liang WC, Ultsch M, Lee CV, Moffat B et al. Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem 2006; 281: 6625-6631.
37. Ulasov IV, Sonabend AM, Nandi S, Khramtsov A, Han Y, Lesniak MS. Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo. Br J Cancer 2009; 100: 1154-1164.